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Abstract
Aims: The risks of thromboembolism and bleeding in patients with atrial fibrillation (AF) and 
valvular heart disease (VHD) are sparsely described. We described the risk of events in non-
anticoagulated and anticoagulated patients with AF and VHD according to the EHRA 
classification, EHRA Type 1 and Type 2 VHD, and within subgroups of EHRA Type 1 and Type 
2 VHD.
Methods and results: Cohort study of AF patients with coexisting VHD, identified in nationwide 
Danish registries from 2000-2018. Risk of thromboembolism and bleeding after 1 year of follow-
up were calculated in each group. We identified 28,770 incident AF patients with VHD. Not 
surprisingly, we observed the highest risks of thromboembolism in the non-anticoagulated AF 
patients with EHRA Type 1 and Type 2 VHD (4.9% vs. 2.6% and 3.2% vs. 1.9%) and the highest 
risks of bleeding in the anticoagulated AF patients with EHRA Type 1 and Type 2 VHD (6.6% vs. 
4.3% and 6.1% vs. 4.9%). However, within the subgroups of AF patients with EHRA Type 1 and 
Type 2 VHD, we observed a large proportion of non-anticoagulated patients (32.9-49.2%), despite 
a CHA2DS2-VASc score of 2≤ in the majority of these patients (81.9-95.6%).
Conclusions: When using data reflecting contemporary clinical practice, we observed markedly 
different risks of thromboembolism and bleeding in EHRA Type 1 and Type 2 VHD. 
Additionally, we observed a potential underuse of oral anticoagulation within the subgroups of AF 
patients with EHRA Type 1 and Type 2 VHD, underlining need for further attention on this 
patient group. 
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What’s already known about this topic:
- Atrial fibrillation (AF) and valvular heart disease (VHD) often coexist. They are independent 
causes of mortality and morbidity, and both have been associated with risk of thromboembolism 
and bleeding events.
- However, no study has thoroughly described the risk of thromboembolism and major bleeding 
according to this newly proposed EHRA classification.
- Specifically, no study has described the risk in subgroups within EHRA Type 1 VHD and EHRA 
Type 2 VHD.  
What does this article add:
- When using data reflecting contemporary clinical practice, we observed markedly different risks 
of thromboembolism and bleeding in EHRA Type 1 and Type 2 VHD, emphasizing the 
differences in these two underlying diseases. 
- Additionally, we observed a potential underuse of oral anticoagulation within the subgroups of 
AF patients with EHRA Type 1 and Type 2 VHD, underlining an unmet need for appropriate 
anticoagulation in this patient group. 
- Future studies examining the optimal antithrombotic treatment strategy in each subgroup of 
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Introduction
Atrial fibrillation (AF) and valvular heart disease (VHD) often coexist [1–3]. They are 
independent causes of mortality and morbidity, and both have been associated with risk of 
thromboembolism and bleeding events [4–6]. Patients with AF have historically been categorized 
as ‘valvular AF’ or ‘non-valvular AF’. However, these terms have lacked clear-cut definitions, 
which challenged physicians and caused confusing terminology in medical research [7–10]. This 
led to the proposal of a new classification of AF patients with VHD: the ‘Evaluated Heartvalves, 
Rheumatic or Artificial’ (EHRA) valve classification, categorizing patients into: (i) EHRA Type 1 
VHD, which refers to AF patients with ‘VHD needing therapy with a Vitamin K antagonist 
(VKA)’ and (ii) EHRA Type 2 VHD, which refers to AF patients with ‘VHD needing therapy 
with a VKA or a non-VKA oral anticoagulant (NOAC)’ [11,12]. EHRA Type 1 VHD comprises 
AF patients with mitral stenosis (moderate-severe, of rheumatic origin) or a mechanical prosthetic 
valve replacement with an indisputable high thromboembolic risk. Guidelines generally agree that 
this group requires lifelong anticoagulation with a VKA. EHRA Type 2 VHD includes AF patients 
with any other heart valve disease or a bioprosthetic valve replacement [11]. The thromboembolic 
risk in this heterogeneous group is more uncertain and, thus, antithrombotic treatment 
recommendations are less consistent.
The EHRA classification has been examined in two previous studies validating the CHA2DS2-
VASc and HAS-BLED scores in AF patients with VHD [12,13]. However, no study has 
thoroughly described the risk of thromboembolism and major bleeding according to the newly 
proposed EHRA classification. Furthermore, EHRA Type 1 VHD and EHRA Type 2 VHD 
include a variety of valve lesions, which may have different etiologies and, therefore, different 
prognoses. Yet, no study has described the risk in these subgroups within EHRA Type 1 VHD and 
EHRA Type 2 VHD. Therefore, the aim of the present study was to describe the risk of 
thromboembolism and major bleeding in non-anticoagulated and anticoagulated patients with AF 
and VHD according to the EHRA classification, EHRA Type 1 and Type 2, and within subgroups 
of EHRA Type 1 and Type 2 VHD.
Methods
Study design and data sources
This study was a register-based nationwide cohort study using data from three Danish nationwide 
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vital and emigration status of all persons living in Denmark [14]; ii) the National Prescription 
Registry [15], which contains data on all prescriptions dispensed from Danish pharmacies since 
1994, coded according to the Anatomical Therapeutic Chemical (ATC) Classification System; iii) 
the Danish National Patient Registry [16], which has registered dates of hospital admissions and 
discharges, outpatient and emergency room contacts, and discharge diagnoses classified according 
to the 10th revision of the International Classification of Diseases (ICD) for more than 99% of 
hospital admissions in Denmark since 1994. The Danish National Patient Registry also holds 
information about surgical procedures and clinical investigations coded according to the Danish 
version of the Nordic NOMESCO Classification of Surgical Procedure provided by the Danish 
Health Data Agency. Data were linked via a unique personal identification number used across all 
Danish national registries.
Study population
The study population consisted of all Danish citizens (age ≥18) with an incident AF diagnosis 
(ICD-10: I48) between January 2000 and July 2018. To focus on AF patients with VHD, only 
patients with a concomitant diagnosis of VHD either prior to or within 30 days after AF diagnosis 
were included. Hospital diagnosis date of incident AF was the index date (baseline) for this study. 
VHD was defined by a diagnosis/procedural code of mechanical prosthetic valve replacement 
(aortic or mitral/mitro-aortic) or mitral stenosis (categorized as EHRA Type 1 VHD) or a 
diagnosis/procedural code of mitral regurgitation, aortic stenosis/regurgitation, bioprosthetic aortic 
valve replacement, bioprosthetic mitral valve replacement, or other valve disease/procedure 
(tricuspid stenosis/regurgitation, pulmonary valve stenosis/regurgitation, or multiple valve disease) 
(categorized as EHRA Type 2 VHD) (See eTable 1 and eTable 2 in the Online Resources for 
details on the definition of EHRA Type 1 VHD and EHRA Type 2 VHD). All patients were 
classified as either EHRA Type 1 VHD or EHRA Type 2 VHD according to diagnostic and 
procedural information at index date. Patients with both a diagnosis in EHRA Type 1 VHD and in 
EHRA Type 2 VHD were classified as EHRA Type 1 VHD. We did not have access to 
echocardiographic data and, therefore, both patients with mild, moderate, and severe VHD were 
included. As oral anticoagulation with a VKA is recommended in all patients with a mechanical 
prosthetic valve replacement, we excluded those patients with a mechanical prosthetic valve 
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since we could not obtain information about the clinical rationale for this inappropriate 
anticoagulation status.
Outcomes
The primary outcomes were thromboembolism (defined as ischemic stroke or systemic embolism) 
and major bleeding (defined as intracranial bleeding, gastrointestinal bleeding, or major clinically 
relevant bleeding located elsewhere) (Detailed information about the definition of the outcomes is 
available in eTable 3 in the Online Resources). Given the severity of the diagnoses of 
thromboembolism, we only considered events if the patient was admitted to the hospital; hence, 
we did not consider outpatient diagnoses for this outcome. Additionally, we only considered 
primary diagnoses of thromboembolism. For the endpoint of major bleeding, both primary and 
secondary diagnoses in out- and inpatient were considered due to clinical coding practice, and to 
allow for full clinical insight (i.e. bleeding leading to hospital contact). Emergency room codes 
were not included due to a general low positive predictive value [17]. All-cause death was 
included as a secondary outcome to elucidate the mortality risk, which may influence the 
methodological approach of estimating absolute risk in a diminishing at-risk population.
Statistical analyses
Baseline characteristics were described separately for patients in subgroups of EHRA Type 1 
VHD and EHRA Type 2 VHD using means/medians and standard deviation (SD)/interquartile 
range (IQR) for continuous variables, and proportions for categorical variables. 
Time-to-event analysis was applied to describe the association between the EHRA categorization 
or subgroup of EHRA Type 1 VHD and EHRA Type 2 VHD and the risk of thromboembolism 
and major bleeding. Time at risk was measured from baseline date and until an event of 
thromboembolism or major bleeding, date of death, emigration, or end of study (November 30, 
2018), whichever came first. Time at risk was measured separately for each event of interest 
(thromboembolism or major bleeding); thus, patients were followed until the event of interest (or a 
censoring event, e.g. death) and were allowed to experience a thromboembolic event before the 
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To depict risk development over time according to subgroups of EHRA Type 1 VHD and EHRA 
Type 2 VHD, we calculated the cumulative incidence of thromboembolism and major bleeding 
based on the Aalen-Johansen estimator taking competing risk of death into consideration [18], 
since this is a group of AF patients with considerable comorbidity and elevated mortality risk. 
Additionally, cumulative incidence curves for all-cause death were constructed to show the 
mortality risk over time in each subgroup. The absolute risks of thromboembolism and major 
bleeding at 1 year after the AF diagnosis were based upon the Aalen-Johansen cumulative 
incidence estimates. The absolute risks were estimated in each group according to the baseline 
status of oral anticoagulant therapy. For the non-anticoagulated group, patients were censored if 
they initiated oral anticoagulant therapy during follow-up. Due to the low number of patients in 
the non-anticoagulated subgroup with a bioprosthetic mitral valve replacements, a reliable risk 
estimate will not be obtainable and, therefore, the absolute risks of events were not calculated in 
this subgroup. Since patients with mitral regurgitation that is related to ischemic heart disease have 
functional different characteristics compared to those without ischemic heart disease, we 
performed a subanalysis estimating the risk of events separately for patients with mitral 
regurgitation with and without coexisting ischemic heart disease (defined as the presence of a 
previous myocardial infarction, percutaneous coronary intervention, or coronary artery bypass 
grafting). Additionally, we described the baseline characteristics of the two subgroups with mitral 
regurgitation in a supplemental table. Furthermore, as the study period extended over a long time 
period (2000-2018), we performed a subanalysis where we split the study period into two time 
spans, 2000-2009 and 2010-2018, and described the risk of events in EHRA Type 1 VHD and 
EHRA Type 2 VHD in the two periods. Statistical analyses were performed using SAS 9.3 (SAS 
Institute) and Stata version 15 (StataCorp LP).
Ethical considerations
This is an observational study. The study was in compliance with the General Data Protection 
Regulation and, therefore, a part of North Denmark Region’s record of processing activities 
(project no. 2017-40). No ethical approval is required for studies based on data from 
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Data for this study, obtained from Danish Health Data Agency, comprise sensitive personal 
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Results
We identified 28,770 incident AF patients with VHD, of which 2,701 patients were categorized as 
EHRA Type 1 VHD and 26,069 patients were categorized as EHRA Type 2 VHD [Fig. 1 in the 
Online Resources].
Baseline patient characteristics
Baseline patient characteristics according to subgroups of EHRA Type 1 VHD and EHRA Type 2 
VHD are summarized in Table 1. Median age ranged from 62 to 76 years among patients with 
EHRA Type 1 VHD and from 74 to 82 years among patients with EHRA Type 2 VHD. 
Percentage of females ranged from 24.7% to 66.9% in patients with EHRA Type 1 VHD and from 
37.8% to 51.9% in patients with EHRA Type 2 VHD. Prevalence of previous thromboembolism 
and mean CHA2DS2-VASc score were highest in patients with isolated mitral stenosis in EHRA 
Type 1 VHD and highest in patients with isolated aortic stenosis in EHRA Type 2 VHD. 
Similarly, the mean HAS-BLED score was highest in patients with isolated mitral stenosis in 
EHRA Type 1 VHD, but highest in patients with bioprosthetic aortic valve replacement in patients 
with EHRA Type 2 VHD. Regarding anticoagulation status at baseline, we observed a large 
proportion of non-anticoagulated patients (32.9-49.2%), despite a CHA2DS2-VASc score of 2 or 
above in the majority of these patients (81.9-95.6%).
Risk of thromboembolism and major bleeding
Both in the non-anticoagulated and anticoagulated patients, cumulative incidence curves depicting 
thromboembolism and major bleeding according to subgroups of EHRA Type 1 VHD and EHRA 
Type 2 VHD demonstrated a steep increase during the first month(s) after AF diagnosis, followed 
by a steady increase during the following months [Fig. 2 and Fig. 3 in the Online Resources]. A 
similar pattern was observed for the endpoint of all-cause death [Fig. 4 in the Online Resources]. 
Separately for the non-anticoagulated and anticoagulated patients, risks of thromboembolism and 
major bleeding after 1 year of follow-up according to EHRA classification and subgroups of 
EHRA Type 1 VHD and EHRA Type 2 VHD are presented in Table 2 and Table 3. Overall, we 
observed the highest risks of thromboembolism in the non-anticoagulated AF patients with EHRA 
Type 1 and Type 2 VHD (4.9% vs. 2.6% and 3.2% vs. 1.9%, respectively) and the highest risks of 
bleeding in the anticoagulated AF patients with EHRA Type 1 and Type 2 VHD (6.6% vs. 4.3% 
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thromboembolism in non-anticoagulated patients with mitral stenosis, both in the anticoagulated 
and non-anticoagulated patients. For the endpoint of major bleeding, we observed the highest risk 
in non-anticoagulated patients with a bioprosthetic aortic valve replacement and in the 
anticoagulated patients with ‘other valve disease/procedure’. Due to the low number of patients in 
the non-anticoagulated subgroup with a bioprosthetic mitral valve replacement, a reliable risk 
estimate will not be obtainable and, therefore, the absolute risks of events were not calculated in 
this subgroup.
Subanalyses
The baseline characteristics of patients with mitral regurgitation and coexisting/no ischemic heart 
disease are described in eTable 4 in the Online Resources. Generally, patients with mitral 
regurgitation and ischemic heart disease were more often males, had a higher prevalence of 
comorbidities such as diabetes, hypertension, heart failure and peripheral artery disease, and were 
more often taking antiplatelet therapy. We observed the highest risk of thromboembolisms in the 
non-anticoagulated patients with ischemic heart disease and the highest risk of major bleeding in 
the anticoagulated patients with ischemic heart disease [eTable 5 in the Online Resources].
When splitting the study period into two time spans, we overall observed similar risks of events in 
the two time spans, except for the non-anticoagulated patients with EHRA Type 1 VHD where the 
risks of events were considerably higher in the time span 2010-2018 [eTable 6 in the Online 
Resources]. Additionally, we observed slightly higher risks of major bleeding in the 
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Discussion
In this nationwide cohort of AF patients with VHD, we overall observed the highest 
thromboembolic risks in the non-anticoagulated AF patients with EHRA Type 1 and Type 2 VHD 
and the highest bleeding risks in the anticoagulated AF patients with EHRA Type 1 and Type 2 
VHD, as expected. However, within the subgroups of AF patients with EHRA Type 1 and Type 2 
VHD we observed a large proportion of non-anticoagulated patients, despite a CHA2DS2-VASc 
score of 2 or above in the majority of these patients.
The proposal of the EHRA classification was an important step to clarify the definition of VHD in 
the AF population and to direct clinicians regarding choice of anticoagulant agent in these 
patients. In our study, we described the risk of thromboembolism and major bleeding in non-
anticoagulated and anticoagulated AF patients with EHRA Type 1 VHD and EHRA Type 2 VHD, 
and in subgroups of EHRA Type 1 VHD and EHRA Type 2 VHD. Our aim was not to compare 
the risk between the EHRA groups or subgroups, as each group/subgroup includes patients with 
several different, probably incomparable, problems with the heart valves. We cannot elucidate 
whether the observed risks are caused by the heart valve disease itself or the presence of other risk 
factors. However, based on the variations in baseline characteristics, including age, comorbidity 
and medicine use, together with the existing knowledge on the thromboembolic physiology of the 
different valve diseases, differences in thromboembolic and major bleeding risk between EHRA 
Type 1 and EHRA Type 2 VHD, and between the subgroups of EHRA Type 1 VHD and EHRA 
Type 2 VHD, were expected.
Previously, only few studies have specifically investigated the thromboembolic and major 
bleeding risks in subgroups of VHD patients with concurrent AF [19–23]. A recent study 
examined the risk of a composite endpoint of ischemic/hemorrhagic stroke and all-cause mortality 
in AF patients with different types of  VHD [22]. However, the study only included patients from 
1998-2010, where the NOACs were not available, and did not specifically examine the endpoint of 
thromboembolism or major bleeding alone. Therefore, our study extends and specifies the findings 
of this previous study and adds important clinical insight since the NOACs have been widely 
adopted into clinical practice for stroke prevention in AF. Since our study period extended over a 
long time period (2000-2018), we performed a subanalysis where we split the study period into 
two time spans, 2000-2009 and 2010-2018. For the time span, where the NOACs were available 
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patients with EHRA Type 2 VHD than in the first time span. However, based on our study we 
cannot make any definitive conclusions regarding this finding, as we did not describe the risk of 
events according to the anticoagulant agent used; thus, further studies are necessary. 
We described the risk of thromboembolism and major bleeding separately for non-anticoagulated 
and anticoagulated patients. Not surprisingly, we overall observed the highest thromboembolic 
risks in the non-anticoagulated AF patients with EHRA Type 1 and Type 2 VHD and the highest 
bleeding risks in the anticoagulated AF patients with EHRA Type 1 and Type 2 VHD. However, 
these estimates should be interpreted with care as the aim of our study was solely to describe the 
risk of thromboembolism and bleeding in AF patients with EHRA Type 1 VHD and EHRA Type 
2 VHD when using data reflecting contemporary clinical practice and not to compare the non-
anticoagulated and anticoagulated patients. Additionally, the proportion of patients in 
antithrombotic therapy at baseline may not accurately describe the association with outcomes due 
to the limitations of assessing medication use using purchase data from registries. For example, the 
baseline antithrombotic medication status was used throughout the follow-up period; thus, 
adherence to therapy is an important, but unknown, factor. We censored patients in the non-
anticoagulated group if they initiated oral anticoagulation during follow-up. However, in the 
anticoagulated patients we did not have information about the quality of anticoagulant control (e.g. 
time in therapeutic range for patients in VKA therapy and actual intake of oral anticoagulants), 
which impact the risk of events [24]. In our study, we observed similar risk of bleeding in the 
anticoagulated and non-anticoagulated patients of some subgroups and similar risk of 
thromboembolism in patients with a mechanical prosthetic valve replacement and in patients with 
EHRA Type 2 VHD despite a lower median age of patients with a mechanical prosthetic valve 
replacement. As our study was not designed to compare the risk in non-anticoagulated versus the 
risk in anticoagulated AF patients with VHD or the risk between subgroups, we can only speculate 
on these observations. Possible differences in baseline characteristics and risk profiles, which 
influence treatment strategy, are likely explanations for the similar risks.
Clinical implications and future research directions
The observations in our study provide the clinician with an overview of the thromboembolic and 
bleeding risks in AF patients with VHD in contemporary clinical practice. Moreover, this large 
study describes the clinical profile and medication status of a nationwide AF population with 
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large proportion of non-anticoagulated patients, despite a CHA2DS2-VASc score of 2 or above in 
the majority of these patients. This observation might be explained by methodological limitations 
of our study (as our aim was not to investigate differences in anticoagulation use), but could also 
reflect an actual underuse of oral anticoagulation for stroke prevention in AF patients with VHD in 
clinical practice. A previous study demonstrated that the lack of a clear-cut definition of ‘valvular 
AF’ until recently has challenged physicians and caused variable antithrombotic treatment strategy 
in these patients, in particular with regard to the use of NOACs [10]. The observed potential 
underuse of oral anticoagulation in AF patients with VHD underline the need for further attention 
on this patient group, both in clinical practice and in research. Future studies examining the 
optimal antithrombotic management in each subgroup of EHRA Type 1 VHD and EHRA Type 2 
VHD are needed. Several studies have examined the effectiveness and safety of NOAC versus 
warfarin in AF patients with VHD, primarily in patients with EHRA Type 2 VHD[25–32]. Meta-
analyses of post-hoc analyses of previous randomized trials examining NOAC versus warfarin in 
AF patients with VHD showed that when pooling the results there was a reduced risk of 
thromboembolism in the NOAC group and no difference in the risk of major bleeding[33–36]. 
However, in several comparative analyses based on real-world data, the benefits of NOAC 
compared to warfarin were inconsistent[25–28,32]. Until more evidence regarding the 
antithrombotic management of this population is available, clinicians are encouraged to use the 
EHRA classification and international guideline recommendations for guidance regarding stroke 
prevention in AF patients with VHD [11].
Our observations indicate that anticoagulated patients with AF and isolated mitral stenosis may be 
a particular high-risk subgroup that requires intensive follow-up. In another recent study from our 
group, we have also made this observation [37]. However, a randomized trial specifically designed 
to investigate the optimal antithrombotic therapy regime in patients with AF and mitral stenosis is 
necessary to make any additional recommendations about the optimal antithrombotic management 
of this subgroup of AF patients with VHD. In Denmark, the majority of the patients with mitral 
stenosis have non-rheumatic mitral stenosis (70% in our study). This influences the 
generalizability of our observations in this subgroup to other populations, where rheumatic disease 
is the dominating cause of mitral stenosis. Additionally, we included all patients with a diagnosis 
of mitral stenosis regardless of the severity of the valve disease and the baseline anticoagulant 
therapy. This could also influence the generalizability of our observations if we primarily included 
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We did not examine individual risk factors of thromboembolism and major bleeding in AF 
patients with different subtypes of VHD, as this analysis was outside the scope of our study; thus, 
we encourage future studies to look into this matter.
Strengths and limitations
The large sample size, uniquely possible with nationwide registry studies, minimizes the risk of 
random error. Bias from a selection into the study was likely low, since we investigated a 
nationwide population cohort of consecutive incident AF patients using administrative data, which 
also implies virtually no loss to follow-up.
The diagnoses of AF and VHD were based on a hospital contact resulting in a diagnosis of AF 
and/or VHD and, therefore, the study population may not be representative of all patients with AF 
and VHD, such as AF patients only seen in general practice. Nevertheless, the diagnosis of AF has 
previously been validated with a positive predictive value of 93% [38,39]. Similarly, the diagnosis 
of different types of VHD have previously been validated with a positive predictive value of 96-
98%, and VHD is generally not diagnosed outside hospitals [40]. We did not have access to 
echocardiographic data and for that reason, we could not report information about the severity of 
the VHD. The risk of thromboembolism and bleeding may be dependent on whether the VHD is 
mild or severe, and therefore, the lack of information on this matter is a limitation. 
In Denmark, every patient presenting with symptoms of a thromboembolism is admitted to and 
examined in a hospital setting. Hence, the accuracy of our findings depends on proper ICD-10 
coding. The diagnosis of ischemic stroke has been validated and found to have a positive 
predictive value of 80-90% [41,42]. However, the risk of ischemic stroke can only be estimated 
with some uncertainty in our study. Firstly, we included unspecified stroke in the definition of 
ischemic stroke, as the majority of such strokes are of ischemic origin [42]. Secondly, we did not 
include transient ischemic attacks due to a low positive predictive value in the registries, and 
thirdly, some patients may experience a fatal stroke and are never admitted to the hospital. Our 
definition of major bleeding only included bleedings leading to a hospital contact, however, some 
bleedings do not lead to a hospital contact and, therefore, these, probably minor, bleedings were 
not included in the endpoint.
According to guidelines, patients with moderate/severe mitral stenosis are recommended 
anticoagulation. However, in our study, some patients with mitral stenosis were not in 
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stenosis or reflect the limitations when assessing the baseline medication status using 
administrative registries. Unfortunately, we could not estimate the severity of the VHD or obtain 
information about the clinical rationale for the anticoagulation status. 
Lastly, the study was carried out as a nationwide study in the Danish population, which is 
ethnically homogeneous; thus, future studies are needed to evaluate if our findings hold in more 
ethnically diverse AF populations.
Conclusions
When using data reflecting contemporary clinical practice, we observed markedly different risks 
of thromboembolism in EHRA Type 1 and Type 2 VHD, and likewise differences in bleeding risk, 
emphasizing the differences in these two underlying diseases. Additionally, we observed a 
potential underuse of oral anticoagulation within the subgroups of AF patients with EHRA Type 1 
and Type 2 VHD, underlining an unmet need for appropriate anticoagulation in this patient group. 
Future studies examining the optimal antithrombotic treatment strategy in each subgroup of EHRA 
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Table 1. Baseline characteristics of patients according to subgroups of EHRA Type 1 VHD and EHRA Type 2 VHD. 

































N 789 1,475 437 10,279 3,343 6,016 4,384 362 1,685 
Age in years, median (IQR) 76 (67-83) 64 (57-71) 62 (55-69) 82 (76-88) 76 (68-82) 74 (66-81) 77 (72-82) 74 (69-80) 76 (67-83) 
Female sex 66.9 (528) 24.7 (365) 41.2 (180) 51.9 (5,337) 46.9 (1,568) 46.9 (2,823) 37.8 (1,658) 39.5 (143) 50.6 (852) 
Comorbidities 
Diabetes mellitus 13.8 (109) 11.7 (173) 8.0 (35) 14.1 (1,445) 6.9 (232) 9.1 (550) 16.4 (721) 11.3 (41) 10.4 (175) 
Hypertension 40.1 (316) 44.2 (652) 26.8 (117) 52.0 (5,348) 51.3 (1,716) 39.0 (2,349) 59.1 (2,593) 42.5 (154) 45.8 (771) 
Heart failure 39.9 (315) 28.8 (425) 40.7 (178) 32.4 (3,326) 27.5 (919) 35.9 (2,161) 32.5 (1,426) 39.8 (144) 34.6 (583) 
Peripheral vascular disease 13.6 (107) 21.8 (322) 5.7 (25) 14.3 (1,467) 18.0 (601) 9.6 (577) 16.2 (711) 9.9 (36) 12.2 (206) 
History of myocardial infarction 14.1 (111) 12.2 (180) 15.3 (67) 18.1 (1,865) 14.3 (479) 17.5 (1,052) 18.2 (800) 24.3 (88) 16.4 (276) 
Pacemaker or implantable 
cardioverter defibrillator 
6.0 (47) 9.6 (141) 12.1 (53) 5.9 (610) 6.2 (208) 5.6 (335) 9.1 (398) 11.3 (41) 6.7 (113) 
Hyperlipidemia/ 
hypercholesterolemia 
17.0 (134) 22.6 (333) 16.9 (74) 16.6 (1,709) 15.8 (527) 16.1 (971) 34.7 (1,522) 23.8 (86) 18.2 (306) 
Chronic kidney disease 9.9 (78) 8.6 (127) 9.2 (40) 9.2 (943) 8.0 (267) 7.1 (430) 12.2 (533) 19.9 (72) 8.5 (144) 
History of cancer 13.8 (109) 10.2 (151) 14.4 (63) 19.5 (2,003) 18.3 (611) 14.7 (886) 16.7 (733) 19.6 (71) 15.4 (260) 
Chronic obstructive pulmonary 
disease 
22.3 (176) 13.4 (198) 16.5 (72) 18.4 (1,891) 17.4 (583) 14.9 (895) 17.8 (780) 14.6 (53) 16.5 (278) 
History of thromboembolism 17.7 (140) 11.3 (167) 12.4 (54) 16.1 (1,651) 13.8 (462) 10.0 (601) 14.1 (619) 14.4 (52) 10.4 (175) 
History of bleeding 19.3 (152) 18.4 (271) 21.3 (93) 19.1 (1,962) 18.4 (614) 15.9 (957) 20.6 (903) 20.2 (73) 16.9 (285) 
 
CHA2DS2-VASc score (mean 
±SD) 
3.8 (1.9) 2.5 (1.8) 2.6 (1.8) 4.1 (1.6) 3.5 (1.8) 3.3 (1.9) 3.9 (1.6) 3.6 (1.7) 3.5 (1.8) 
HAS-BLED score (mean ±SD) 2.4 (1.3) 1.9 (1.3) 1.8 (1.2) 2.6 (1.1) 2.4 (1.2) 2.2 (1.2) 2.9 (1.1) 2.7 (1.1) 2.4 (1.2) 
Charlson comorbidity index score 
(mean ±SD) 
1.5 (1.7) 1.2 (1.6) 1.3 (1.7) 1.6 (1.8) 1.4 (1.8) 1.2 (1.7) 1.6 (1.8) 1.6 (2.0) 1.2 (1.7) 
Time since VHD diagnosis: 
Within 6 months before index 
date 
36.8 (290) 33.1 (488) 30.9 (135) 41.5 (4,261) 34.1 (1,139) 42.3 (2,543) 36.4 (1,597) 44.2 (160) 34.9 (588) 
Median, days (IQR) 526 (1-2,106) 881 (21-3,231) 1,295 (72-3,305) 315 (0-1,425) 702 (0-2,350) 283 (0-1,894) 622 (87-2,112) 295 (44-1,680) 901 (6-2,453) 
Comedication† 
Beta-blockers 55.8 (440) 66.5 (981) 65.4 (286) 58.8 (6,041) 62.8 (2,098) 62.4 (3,751) 66.2 (2,904) 60.2 (218) 60.8 (1,025) 
ARB/ACE-inhibitors 43.0 (339) 52.0 (767) 49.7 (217) 46.8 (4,807) 55.4 (1,851) 54.9 (3,302) 54.4 (2,383) 53.6 (194) 50.8 (856) 
Calcium channel blockers 25.0 (197) 27.8 (410) 17.8 (78) 35.2 (3,614) 32.9 (1,100) 25.3 (1,521) 32.8 (1,440) 19.1 (69) 29.4 (496) 
Amiodarone 7.4 (58) 21.2 (312) 17.8 (78) 6.7 (692) 5.7 (189) 8.9 (533) 22.1 (968) 17.1 (62) 5.5 (92) 
Digoxin 38.4 (303) 15.9 (234) 27.5 (120) 31.5 (3,239) 24.9 (831) 34.8 (2,093) 15.9 (699) 17.7 (64) 30.1 (507) 
Non-loop diuretics 37.3 (294) 38.0 (561) 35.9 (157) 44.7 (4,596) 40.8 (1,364) 38.2 (2,298) 43.8 (1,918) 37.8 (137) 43.6 (735) 
Loop diuretics 61.2 (483) 45.1 (665) 57.9 (253) 57.6 (5,917) 41.8 (1,399) 52.7 (3,172) 58.8 (2,579) 62.2 (225) 54.2 (913) 
NSAIDs 16.1 (127) 18.1 (267) 13.0 (57) 14.9 (1,533) 16.0 (536) 14.7 (886) 16.6 (728) 11.6 (42) 16.0 (270) 
Statins 38.3 (302) 45.3 (668) 33.9 (148) 39.6 (4,068) 35.9 (1,201) 33.4 (2,010) 60.6 (2,655) 42.5 (154) 36.0 (607) 
Antithrombotic therapy: § 
   Aspirin 46.1 (364) 38.1 (562) 29.5 (129) 50.8 (5,218) 45.8 (1,530) 46.4 (2,789) 67.1 (2,943) 51.1 (185) 49.2 (829) 
   Other antiplatelet 8.7 (69) 3.8 (56) 3.0 (13) 13.0 (1,341) 9.4 (314) 7.6 (458) 16.1 (705) 9.4 (34) 8.8 (148) 
   No oral anticoagulant therapy 37.5 (296)     -     - 49.2 (5,060) 45.7 (1,527) 40.7 (2,448) 34.9 (1,529) 32.9 (119) 45.9 (773) 
 CHA2DS2-VASc score = 0 3.4 (10)     -     - 1.0 (51) 6.4 (98) 6.5 (158) 1.1 (17)   - ¶ 4.8 (37) 
 CHA2DS2-VASc score = 1 6.8 (20)     -     - 3.4 (174) 9.4 (144) 11.6 (285) 5.1 (78)   - ¶ 9.2 (71) 
 CHA2DS2-VASc score = 2+ 89.9 (266)     -     - 95.6 (4,835) 84.2 (1,285) 81.9 (2,005) 93.8 (1,434)   - ¶ 86.0 (665) 
   Vitamin K antagonists/VKA 54.0 (426) 100.0 (1,475) 100.0 (437) 33.1 (3,398) 34.3 (1,148) 44.5 (2,676) 48.0 (2,103) 53.0 (192) 42.9 (723) 
   Non-vitamin K antagonist oral 
anticoagulants/NOAC 
8.5 (67) 0.0 (0) 0.0 (0) 17.7 (1,821) 20.0 (668) 14.8 (892) 17.2 (752) 14.1 (51) 11.2 (189) 
Oral anticoagulant therapy  
(patients included in 2016-2018): 
         
   No oral anticoagulant therapy 25.0 (24)   -   -  29.2 (563) 25.8 (170) 25.6 (230) 29.7 (278) 25.8 (25) 32.0 (62) 
   Vitamin K antagonists/VKA 39.6 (38) 100.0 (195) 100.0 (47) 17.6 (339) 16.8 (111) 19.8 (178) 19.6 (183) 42.3 (41) 17.5 (34) 
   Non-vitamin K antagonist oral 
anticoagulants/NOAC 
35.4 (34) 0.0 (0) 0.0 (0) 53.2 (1,025) 57.4 (378) 54.7 (492) 50.7 (475) 32.0 (31) 50.5 (98) 
All numbers are in % with number of patients in brackets, unless otherwise stated. 
Abbreviations: ACE: Angiotensin converting enzyme, ARB: Angiotensin II receptor blocker, CHA2DS2-VASc: Congestive heart failure or left ventricular disease, hypertension, age≥75, diabetes, stroke, 
vascular disease, age>65, female sex, EHRA: Evaluated Heartvalves, Rheumatic or Artificial valve classification, HASBLED: Hypertension, age>65, stroke, prior bleeding, labile INR, liver or kidney 
disease, medication predisposing bleeding or alcohol use, IQR: Interquartile range, NSAID: Non-steroidal anti-inflammatory drug, SD: Standard deviation, VHD: Valvular heart disease. 
†Patients with a redeemed prescription within 180 days prior to or 30 days after the diagnosis of atrial fibrillation. 
‡Patients with tricuspid stenosis/regurgitation, pulmonary valve stenosis/regurgitation, or multiple valve disease. 
§Antithrombotic therapy status at baseline, based on information from the entire study period (2000-2018). 
¶Exact number not allowed to be shown due to General Data Protection Regulations of The Danish Health Data Agency. 
Table 2. Absolute risk of thromboembolism and major bleeding at 1 year after AF diagnosis according to EHRA classification and 
anticoagulation status at baseline. 
EHRA classification 
(number of patients) 
EHRA Type 1 VHD EHRA Type 2 VHD 








Absolute risk at 1 year of follow-up†,  
% (number of events) 
Thromboembolic event 4.9 (13) 2.6 (63) 3.2 (333) 1.9 (277) 
Major bleeding event‡ 4.3 (11) 6.6 (158) 4.9 (498) 6.1 (884) 
Abbreviations: EHRA classification: Evaluated Heartvalves, Rheumatic or Artificial valve classification, OAC: Oral anticoagulation, VHD: 
Valvular heart disease. 
†Calculated using the Aalen-Johansen estimator taking competing risk of death into consideration. 
‡Defined as intracranial bleeding, gastrointestinal bleeding, or major clinically relevant bleeding located elsewhere. 
  
Table 3. Absolute risk of thromboembolism and major bleeding at 1 year after AF diagnosis according to subgroups of EHRA Type 1 VHD and 
EHRA Type 2 VHD and anticoagulation status at baseline. 

































Absolute risk at 1 year of follow-up†,   
% (number of events) 
No OAC therapy (number of patients) (296)   -    - (5,060) (1,527) (2,448) (1,529) (119) (773) 
Thromboembolic event 4.9 (13)   -    - 3.7 (169) 3.1 (43) 3.0 (67) 2.2 (29)   - 3.2 (22) 
Major bleeding event‡ 4.3 (11)   -    - 4.9 (226) 3.7 (51) 4.9 (105) 5.8 (77)   - 4.9 (34) 
 
OAC therapy (number of patients) (493) (1,475) (437) (5,219) (1,816) (3,568) (2,855) (243) (912) 
Thromboembolic event 4.7 (23) 1.8 (26) 3.2 (14) 2.6 (135) 2.0 (36) 1.5 (53) 1.2 (34) 2.1 (5) 1.5 (14) 
Major bleeding event‡ 6.6 (32) 6.5 (96) 6.9 (30) 7.2 (372) 5.3 (95) 4.5 (161) 5.7 (162) 7.5 (18) 8.4 (76) 
Abbreviations: EHRA classification: Evaluated Heartvalves, Rheumatic or Artificial valve classification, OAC: Oral anticoagulation, VHD: Valvular heart disease. 
†Calculated using the Aalen-Johansen estimator taking competing risk of death into consideration. 
‡Defined as intracranial bleeding, gastrointestinal bleeding, or major clinically relevant bleeding located elsewhere. 
§Due to the low number of patients in the non-anticoagulated subgroup with a bioprosthetic mitral valve replacement, a reliable risk estimate will not be obtainable and, therefore, the absolute risks of events 
were not calculated in this subgroup. 
¶ Patients with tricuspid stenosis/regurgitation, pulmonary valve stenosis/regurgitation, or multiple valve disease. 
